Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells

Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells

Abstract Medulloblastoma (MB) is the most common aggressive paediatric brain tumour and, despite the recent progress in the treatments of MB patients, there is still an urgent need of complementary or alternative therapeutic options for MB infants. Cyclin Dependent Kinase inhibitors (CDKi) are at th...

Full description

Bibliographic Details
Main Authors: Marta Buzzetti, Sonia Morlando, Dimitrios Solomos, Ammara Mehmood, Alexander W. I. Cox, Mattia Chiesa, Yuri D’Alessandra, Michela Garofalo, Caroline H. Topham, Gianpiero Di Leva
Format: Article
Language:English
Published: Nature Publishing Group 2021-03-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-84082-3

Internet

https://doi.org/10.1038/s41598-021-84082-3

Similar Items